AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

December 3, 2019 GMT

TAMPA, Fla.--(BUSINESS WIRE)--Dec 3, 2019--

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. will be a featured presenter at the LD Micro Main Event on Tuesday, December 10, 2019 at 1:00 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Dr. Joslyn will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings.

For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allows Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191203005063/en/

CONTACT: Oragenics, Inc.

Corporate:

Michael Sullivan, 813-286-7900

Chief Financial Officer

msullivan@oragenics.com

or

Investors:

John Marco

Managing Director

CORE IR

516-222-2560

johnm@coreir.comMedia:

Jules Abraham

CORE IR

917-885-7378

julesa@coreir.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA FLORIDA

INDUSTRY KEYWORD: HEALTH OTHER SCIENCE RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: Oragenics, Inc.

Copyright Business Wire 2019.

PUB: 12/03/2019 08:30 AM/DISC: 12/03/2019 08:30 AM

http://www.businesswire.com/news/home/20191203005063/en